Objective: To analyze the differences of the clinical characteristics and risk factors between tumor and non-tumor patients complicated with pulmonary embolism. Methods: A retrospective analysis was conducted on 96 hospitalized patients complicated with pulmonary embolism admitted into 307 Hospital of PLA from January 2009 to December 2014. 96 cases were divided into tumor group (n=52) and non-tumor group (n=44) according to whether they were accompanied with malignant tumors. The relevant characteristics of tumor group, comparison of the risk factors and laboratory results between two groups were assessed. Results: Lung cancer was prone to pulmonary embolism in malignant tumors and adenocarcinoma was the commonest pathological type. 31 (59.6%) cases developed pulmonary embolism within 3 months after tumor was diagnosed. The level of serum D-dimer and leukemia in tumor group were higher than that in non-tumor group (3241.06±4514.16 μg/L vs 1238.49±1236.69 μg/L and 9.68±5.53×109/L vs 7.90±3.84×109/L), with a significant statistical difference (P=0.004 and 0.015). The level of serum platlet in tumor group were lower than that in non-tumor group (204.63±132.58×109/L vs 222.26±76.92×109/L), with a significant statistical difference (P=0.023). Coronary heart disease, chronic lung disease, diabetes, hyperlipemia and cerebral infarction were significantly different between two groups (P<0.01). Unexplained dyspnea (51/96, 53.1%) was the main symptom of pulmonary embolism, yet no significant difference was found between the two groups. 33 cases (34.4%) combined with deep venous thrombosis of lower limb, right lower limb more than the left. Right main pulmonary artery and its branches embolism were seen in 46 cases (47.9%) according to imaging examination, and no significant difference between two groups. After thrombolytic and anticoagulant therapy, only 9 cases died of Pulmonary embolism. Conclusion: There is no obvious and significant difference in clinical symptoms between tumor and non-tumor patients complicated with pulmonary embolism. Using of anticoagulant and thrombolytic therapy can obtain good curative effect upon diagnosis.
展开▼
机译：目的：分析肿瘤与非肿瘤合并肺栓塞患者的临床特点和危险因素的差异。方法：回顾性分析2009年1月至2014年12月收治于解放军307医院的96例并发肺栓塞的住院患者。将96例患者分为肿瘤组（n = 52）和非肿瘤组（n = 44）。根据他们是否伴有恶性肿瘤。评估两组肿瘤的相关特征，危险因素的比较和实验室检查结果。结果：恶性肿瘤中肺癌易发生肺栓塞，腺癌是最常见的病理类型。在诊断出肿瘤后的三个月内，有31（59.6％）例发生了肺栓塞。肿瘤组的血清D-二聚体和白血病水平高于非肿瘤组（3241.06±4514.16μg/ L分别为1238.49±1236.69μg/ L和9.68±5.53×10 9 / L vs 7.90±3.84×10 9 / L），差异有统计学意义（P = 0.004和0.015）。肿瘤组血清血小板水平低于非肿瘤组（204.63±132.58×10 9 / L vs 222.26±76.92×10 9 / L） ，具有显着的统计差异（P = 0.023）。两组的冠心病，慢性肺病，糖尿病，高脂血症和脑梗死有显着性差异（P <0.01）。原因不明的呼吸困难（51 / 96，53.1％）是肺栓塞的主要症状，但两组之间无明显差异。 33例（34.4％）合并下肢深静脉血栓形成，右下肢多于左侧。影像学检查发现右主肺动脉及其分支栓塞46例，占47.9％，两组无明显差异。经过溶栓和抗凝治疗后，只有9例死于肺栓塞。结论：肿瘤与非肿瘤合并肺栓塞的临床症状无明显差异。诊断时使用抗凝和溶栓治疗可获得良好的疗效。
展开▼
